Understanding the New Treatment Era of Alternative Therapies for Patients With Hemophilia A
  • CME

In this on-demand Webcast, Guy A. Young, MD, reviews new therapies available to treat Hemophilia A.
Guy A. Young, MD
Program Director
Michael Callaghan, MD
Stacy Croteau Headshot
Stacy E. Croteau, MD, MMS
Miguel A. Escobar, MD
person default
Cindy A. Leissinger, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: June 28, 2019 Expiration: June 27, 2020

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Implement individualized hemophilia management strategies that optimize adherence, outcomes, and utilization of resources
  • Describe novel approaches to treating patients with hemophilia and inhibitors
  • Review the strengths and limitations of outcome measures used currently in hemophilia clinical practice/research and ongoing efforts to develop novel outcome measures that address these common limitations

Information on this Educational Activity

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director

Guy A. Young, MD

Professor of Pediatrics
Hemostasis and Thrombosis Center
Children's Hospital Los Angeles
University of Southern California Keck School of Medicine
Los Angeles, California

Guy A. Young, MD, has received contracted research support from Genentech, fees for non-CME services from Bioverativ and Genentech, and consulting fees from CSL Behring, Genentech/Roche, Kedrion, Novo Nordisk, Pfizer, and Shire.


Michael Callaghan, MD

Associate Professor
Department of Hematology
Wayne State University
Division of Hematology/Oncology
Children's Hospital of Michigan
Detroit, Michigan

Michael Callaghan, MD, has received consulting fees from Bioverativ, Genentech/Roche, Pfizer, and Shire, and has ownership interest in Alnylum.
Stacy E. Croteau, MD, MMS

Assistant Professor of Pediatrics
Department of Hematology
Boston Children's Hospital
Harvard Medical School
Boston, Massachusetts

Stacy E. Crouteau, MD, MMS, has received contracted research support from Boehringer Ingelheim, Genentech, Hemophilia of Georgia, Octapharma, Pfizer, and Spark Therapeutics, and consulting fees from Bayer, Biomarin, Bioverativ, Catalyst Biosciences, CSL-Behring, Genentech, Novo Nordisk, and Octapharma.
Miguel A. Escobar, MD

Professor of Medicine and Pediatrics
Department of Hematology
University of Texas Health Science Center
McGovern Medical School
Gulf States Hemophilia and Thrombophilia Center
Houston, Texas

Miguel A. Escobar, MD, has received contracted research support from Genentch, Novo Nordisk, Sanofi, and Takeda, and consulting fees from CSL-Behring, Genentech/Roche, Novo Nordisk, Pfizer, Sanofi, and Takeda/Shire.
Cindy A. Leissinger, MD

Louisiana Center for Bleeding and Clotting Disorders
New Orleans, Louisiana

Cindy A. Leissinger, MD, has received contracted research support from Biomarin and Genentech/Roche, and has received consulting fees from Bayer, CSL Behring, Genetech/Roche, Hemabiologics, Kedrion, Novo Nordisk, Shire/Takeda, Spark and uniQure.


Krista Marcello

Associate Director, Educational Strategy

Krista Marcello has no real or apparent conflicts of interest to report.
Taryn O'Loughlin Gross, PhD

Editorial Contributor

Taryn O’Loughlin Gross, PhD, has disclosed that she has received fees from non-CME services from Harmony Biosciences, Salix, Saluda Medical, and Shionogi.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no real or apparent conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin L. Obholz, PhD, has no real or apparent conflicts of interest to report.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The PIM planners and managers have nothing to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for hematologists and other healthcare providers who care for patients with hemophilia.


The goal of this activity is to improve participants’ competence in treating patients with hemophilia.


Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 28, 2019, through June 27, 2020:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Avelumab maintenance following first-line platinum-based chemotherapy in advanced urothelial carcinoma from ASCO 2020 as reported by Clinical Care Options (CCO)

Released: June 3, 2020

Data presented at ASCO 2020 on exploratory biomarker analyses from the phase III CheckMate 214 trial, as reported by Clinical Care Options (CCO)

Released: June 3, 2020

ASCO 2020 data on treatment with nivolumab plus brentuximab vedotin in standard-risk young patients with R/R classical Hodgkin lymphoma as reported by Clinical Care Options (CCO)

Released: June 3, 2020

Results from BYLieve Cohort A with alpelisib plus fulvestrant in PIK3CA¬-mutated HR+/HER2- advanced breast cancer post-CDK4/6i, from ASCO 2020 as reported by Clinical Care Options (CCO)

Released: June 3, 2020
Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)

This activity is supported by an educational grant from

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?